Ken Griffin Sensei Biotherapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 57,717 shares of SNSE stock, worth $27,704. This represents 0.0% of its overall portfolio holdings.
Number of Shares
57,717
Previous 66,044
12.61%
Holding current value
$27,704
Previous $39,000
28.21%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SNSE
# of Institutions
26Shares Held
2.39MCall Options Held
0Put Options Held
0-
Ikarian Capital, LLC Dallas, TX650KShares$311,9820.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA594KShares$285,3370.0% of portfolio
-
Catalio Capital Management, LP New York, NY294KShares$141,2990.03% of portfolio
-
Boothbay Fund Management, LLC New York, NY173KShares$82,9430.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny157KShares$75,2640.0% of portfolio
About Sensei Biotherapeutics, Inc.
- Ticker SNSE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,720,300
- Market Cap $14.7M
- Description
- Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...